作为PARP抑制剂耐药卵巢癌的潜在治疗标,RECQL1被认为是一个潜在的治疗标
Hiroyuki Yoshida1, Jiarui Li2, Hiroaki Inui3
1Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan. hiro_y@saitama-med.ac.jp.
Scientific reports
|October 31, 2025
概括
高RECQL1表达与卵巢癌中对olaparib反应不佳相关. 准RECQL1可以克服多 (ADP-ribose) 聚合酶抑制剂耐药性,改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 卵巢癌的治疗面临的挑战是对多 (ADP-ribose) 聚合酶 (PARP) 抑制剂的耐药性.
- 了解耐药性机制对于改善患者的治疗结果至关重要.
研究的目的:
- 研究RECQL1,一个RecQ酶在克服卵巢癌中PARP抑制剂耐药性的作用.
- 评估RECQL1作为潜在的治疗点.
主要方法:
- 在44名接受olaparib治疗的卵巢癌患者中通过免疫组织化学评估RECQL1蛋白表达.
- 在实验室中使用siRNA评估了RECQL1淘汰的效果.
- 进行了卡普兰-梅尔和多变量分析,以确定生存结果.
主要成果:
- 没有对olaparib反应的患者显示RECQL1表达显著增加 (P=0.020).
- 高RECQL1表达与较短的整体存活率 (P=0.027) 有关,并且是显著的预后因素 (P=0.036).
- 在卵巢癌细胞系中,RECQL1敲击增强了对olaparib的敏感性.
结论:
- 在卵巢癌中,RECQL1关键参与了PARP抑制剂耐药性.
- RECQL1是一个有前途的治疗点,可以提高治疗效率和患者的治疗结果.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K